2020年10月，在《Journal of Lower Genital Tract Disease》发表了一篇关于2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors指南共识的勘误。
文章中及时纠正了一些错误信息，现小编将相关内容整理如下，供临床参考，大家在借鉴指南时注意要替换成正确内容哦！
原文章中关于图2的描述为：
“对于常见的低级别筛查异常(hpv阳性ASC-US)患者如何在风险评估的基础上进行管理。初筛结果直接转诊阴道镜（即时风险为4.2%），阴道镜结果＜CIN2，5年风险为3.2%（1年后复查）。1年复查结果中，第二次hpv阳性ASC-US 的即时风险为3.1% (1年后复查)。如果患者在下一次随访时再次出现异常筛查，推荐阴道镜检查。如果hpv检测为阴性，建议3年后复查。NA，不适用，因为没有稳定的风险评估。”
The figure legend for Figure 2 states, “FIGURE 2: This figure demonstrates how a patient with a common low-grade screening abnormality (HPV-positive ASC-US) would be managed based on risk estimates. The initial screening result would lead to colposcopy (immediate risk 4.2%). Colposcopy of less than CIN 2 has a 5-year risk of 3.2% (1-year return). At the 1-year return visit, a second HPV-positive ASC-US result has an immediate risk of 3.1% (1-year return). If the patient has a repeat abnormal screen at the next follow-up, colposcopy is recommended. If the HPV-based test is negative, return in 3 years is recommended. NA, not applicable because stable risk estimates are not available.”
勘误中将图2描述更新为：
“如何对常见的轻度异常筛查结果(hpv阳性ASC-US)的患者根据风险评估进行管理。初筛结果直接转诊阴道镜（即时风险为4.45%），如果阴道镜结果＜CIN2，那么5年风险为2.9%（1年后复查）。1年后复查，第二次结果仍为hpv阳性ASC-US 的即时风险为3.1% (1年后复查)。注:如果在阴道镜检查前的初筛结果有轻度的异常 (即小于ASC-H)，则推荐采用类似的管理办法。如果进行第二次阴道镜检查后HPV检测为阴性，建议3年后复查。如果第二次阴道镜检查后的检测结果是HPV检测呈阳性且有任一细胞学结果，或者HPV检测呈阴性且细胞学结果为ASC-H或更高，建议进行阴道镜检查。结果HPV阴性细胞学ASCUS或LSIL推荐一年后复查。NA，不适用，因为没有稳定的风险评估。”
However, this legend has been updated to read, “This figure demonstrates how a patient with a common minimally abnormal screening test result (HPV-positive ASC-US) would be managed based on risk estimates. The initial screening result would lead to colposcopy (immediate risk 4.45%). If colposcopy shows less than CIN 2, the 5-year risk is 2.9% (1-year return). At the 1-year return visit, a second HPV-positive ASC-US result has an immediate risk of 3.1% (1-year return). Note similar management would be recommended if the initial abnormality preceding colposcopy were any minimally abnormal test result (i.e., less severe than ASC-H). If the HPV-based test performed for the second post-colposcopy surveillance test is negative, return in 3 years is recommended. If the second post-colposcopy surveillance test results are either a positive HPV test with any cytology result or a negative HPV test result with a cytology result of ASC-H or higher, colposcopy is recommended. Return in 1 year is recommended for HPV-negative ASCUS or LSIL results.
